‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System
The way in which pharmaceuticals might be regulated in the UK after the country leaves the EU is a big unknown. As MPs get to have their say on the matter, the Pink Sheet tries to gauge government thinking.
You may also be interested in...
The extent of the UK medicines regulator’s involvement in the European regulatory network shows how complicated disentangling the UK from the system would be.
Liam Fox, one of the ministers in charge of leading the UK out of the EU, does not want the country to stay within the wider European drug regulatory system, even though many in the life science sector see this as vital if regulatory divergence and drug marketing delays are to be avoided.
Parliament may get to vote on the terms of the UK’s departure from the EU if an important legal decision handed down today is upheld. Industry has its eye on ongoing talks with the government.